{"id":7199,"date":"2025-03-21T16:53:00","date_gmt":"2025-03-21T07:53:00","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=7199"},"modified":"2025-04-03T16:56:04","modified_gmt":"2025-04-03T07:56:04","slug":"20250321-2","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2025\/03\/21\/20250321-2\/","title":{"rendered":"HIROTSU Bioscience CEO Talks Nasdaq Strategy at BEYOND 2020 &#8220;INNOVATION DAY&#8221;"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Tokyo, Japan \u2013 [February 28, 2025] \u2013 HIROTSU Bioscience CEO Takaaki Hirotsu participated as a panelist at BEYOND 2020 NEXT FORUM &#8220;INNOVATION DAY&#8221;, held on February 28 at Tokyo Innovation Base. This high-profile event brought together leading innovators, entrepreneurs, and policymakers to drive forward Japan\u2019s post-2020 transformation.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/hbio.jp\/news\/wp-content\/uploads\/2025\/03\/image0-1024x683.jpeg\" alt=\"\" class=\"wp-image-7149\" srcset=\"https:\/\/hbio.jp\/news\/wp-content\/uploads\/2025\/03\/image0-1024x683.jpeg 1024w, https:\/\/hbio.jp\/news\/wp-content\/uploads\/2025\/03\/image0-300x200.jpeg 300w, https:\/\/hbio.jp\/news\/wp-content\/uploads\/2025\/03\/image0-768x512.jpeg 768w, https:\/\/hbio.jp\/news\/wp-content\/uploads\/2025\/03\/image0-1536x1024.jpeg 1536w, https:\/\/hbio.jp\/news\/wp-content\/uploads\/2025\/03\/image0.jpeg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;INNOVATION DAY&#8221; featured three key sessions: \u201cNASDAQ Success Strategies,\u201d \u201cThe Power of Social Impact,\u201d and \u201cEntertainment NEXT.\u201d Dr. Hirotsu participated in the NASDAQ Success Strategies panel, sharing insights on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>N-NOSE, the company\u2019s groundbreaking nematode-based cancer detection technology.<\/li>\n\n\n\n<li>Opportunities in the global cancer diagnostics market.<\/li>\n\n\n\n<li>Why HIROTSU Bioscience is targeting a Nasdaq listing over domestic exchanges.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">As HIROTSU Bioscience positions itself as a leader in early cancer detection, its Nasdaq aspirations signal a strategic push for global expansion and investor engagement. The company\u2019s pioneering N-NOSE testing platform has the potential to disrupt traditional diagnostics, offering a non-invasive, cost-effective, and highly sensitive approach to early cancer screening.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.youtube.com\/watch?v=rzQL6DQWeUQ\">The full session was streamed live and is available for viewing here (Japanese only). &#8211; insert link<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.tokyoheadline.com\/793255\/\">For more information about BEYOND 2020 NEXT FORUM, visit Tokyo Headline. &#8211; insert link<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tokyo, Japan \u2013 [February 28, 2025] \u2013 HIROTSU Bioscience CEO Takaaki Hirotsu participated as a panelist at BEYO [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"https:\/\/hbio.jp\/news\/?p=7144","footnotes":""},"categories":[2],"tags":[],"class_list":["post-7199","post","type-post","status-publish","format-standard","hentry","category-news","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/7199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=7199"}],"version-history":[{"count":1,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/7199\/revisions"}],"predecessor-version":[{"id":7200,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/7199\/revisions\/7200"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=7199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=7199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=7199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}